KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Equity Average (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Equity Average for 17 consecutive years, with $51.9 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 42.71% to $51.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $51.9 billion through Dec 2025, up 42.71% year-over-year, with the annual reading at $50.2 billion for FY2025, 152.19% up from the prior year.
  • Equity Average hit $51.9 billion in Q4 2025 for Abbott Laboratories, up from $22.2 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $51.9 billion in Q4 2025 to a low of -$7.2 billion in Q1 2021.
  • Historically, Equity Average has averaged $7.2 billion across 5 years, with a median of $220.8 million in 2021.
  • Biggest five-year swings in Equity Average: crashed 2009.44% in 2022 and later skyrocketed 1518.03% in 2024.
  • Year by year, Equity Average stood at $219.0 million in 2021, then crashed by 1890.41% to -$3.9 billion in 2022, then decreased by 19.17% to -$4.7 billion in 2023, then skyrocketed by 877.78% to $36.3 billion in 2024, then soared by 42.71% to $51.9 billion in 2025.
  • Business Quant data shows Equity Average for ABT at $51.9 billion in Q4 2025, $22.2 billion in Q3 2025, and -$7.0 billion in Q2 2025.